In an agency first, the FDA has cleared a system designed to clean out the complex inner channels of flexible endoscopes—a ...
Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...
Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.
A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
The agency has also removed 91 federal sites previously listed on its “wall of receipts” for planned lease cancellations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback